Year: 2018

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below. Resolution For % For Against % Against Withheld 1. To receive the accounts of the Company for the year…

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to confirm that the Company’s Annual General Meeting (“AGM”) will be held on Friday 28 June 2024 @ 11:00a.m. (BST), at the offices of Evelyn Partners, 45 Gresham Street, London, EC2V 7BG. The Notice of AGM setting out details of the…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its Final Results for the twelve months ended 31 December 2023 (the “Period”). Key Highlights (including post Period review) Financials Loss for the Period of £2.9m (2022:  £3.8m) Research and development expenses of £2.0m (2022: £2.0m) Administrative expenses of £1.0m (2022: £0.8m)…

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, announces that it has realised gross proceeds of c£1.5 million on the sale of its entire holding of c9.9 million shares in Incanthera plc. Following this transaction, ImmuPharma retains c7.3 million warrants in Incanthera plc which have an exercise price of 9.5p and…

To download details click here

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be attending BIO-Equity. The event will be held from 12-14 May 2024, in San Sebastian, Spain. BIO-Equity is an annual premier partnering event, designed to provide biotechnology companies with the opportunity to present to…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of unapproved share options over ordinary shares of 1 penny each to directors as follows. Lisa Baderoon     3,000,000 share options (exercise price: 2.24p) Laurence Reilly   2,000,000 share options (exercise price: 2.24p) Share Option Period: All Share Options are valid for 10…

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce that it has initiated a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform. P140 is ImmuPharma’s technology platform for its portfolio in autoimmune diseases. This comprises the lead indication…

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is delighted to highlight the announcement issued this morning by Incanthera plc (“Incanthera”), the dermatology and oncology specialist, in which ImmuPharma currently holds a 10.8% shareholding. Within the announcement, Incanthera announces an update on its commercial skincare deal, announced in December 2023, with…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows. The Remuneration Committee (comprising the Non-Executive Directors) has determined that the following unapproved Share Options have been awarded to the Executive Directors with vesting  conditions which reflect the corporate objective of restoring and enhancing shareholder value as…